<DOC>
	<DOC>NCT02105584</DOC>
	<brief_summary>This is a prospective, non-randomized, study of the safety and efficacy of the Occlutech® LAA occluder indicated for percutaneous LAA closure in adult male or female patients with atrial fibrillation. Safety and efficacy will be assessed at day 1, 30 and 90, and after 1 year following implantation of an Occlutech® LAA Occluder.</brief_summary>
	<brief_title>Prospective, Non-randomized, Safety and Efficacy Study of a New Occluder Design for Minimally Invasive Closure of the Left Atrial Appendage (LAA) in Patients With Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Documented paroxysmal, persistent or chronic nonvalvular AF Calculated CHA2DS2 VASC score equal or greater than 2 and/or HASBLED score equal or greater than 2 Patients eligible or noneligible for lifelong, oral anticoagulation therapy Life expectancy of at least 1 year Written, informed consent by the patient or her/his legallyauthorized representative for participation in the study Suspected or known intracardiac thrombus NYHA Class IV CHF Patients who has unstable and intractable angina pectoris ASD and/or atrial septal repair or closure device Recent myocardial infarction within 3 months Severe valvular heart disease, or implanted mechanical valve prosthesis Large PFO with significant atrial septal aneurysm Planned ablation procedure within 30 days of Occlutech LAA occluder® implant Resting heart rate &gt; 110 bpm Allergy to Nitinol, which is a result of nickel and/or titanium allergies Stroke/TIA within the last 30 days Thrombocytopenia, thrombocytosis, leukopenia, or anemia Symptomatic carotid artery disease LVEF &lt; 30% Mitral valve stenosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>